Kemp Dolliver

Serge Belanger

Stacy Ku

Anish Nikhanj

Glen Santangelo

Gregory Renza

John Todaro

Oren Livnat

- **Veradermics** announced the completion of an **oversubscribed $150 million Series C financing**.  **[1660334_28190089a25f4c579e6f35c03e011a76_0]** 
- The proceeds are intended to fund the advancement of **VDPHL01**, an investigational extended-release oral minoxidil, through multiple ongoing **Phase 3 clinical trials** and a planned New Drug Application (NDA) submission for the treatment of pattern hair loss.  **[1660334_28190089a25f4c579e6f35c03e011a76_0]** **[1660334_28190089a25f4c579e6f35c03e011a76_1]** 
- Preliminary **Phase 2 data in males** for VDPHL01 showed visible and measurable hair growth as early as two months, with an average increase of **37.5 hairs/cm2** from baseline at two months and **47.3 hairs/cm2** at four months.  **[1660334_28190089a25f4c579e6f35c03e011a76_0]** **[1660334_28190089a25f4c579e6f35c03e011a76_2]** 
- The financing was led by **SR One**, with participation from new investors including **Viking Global Investors** and **Marshall Wace**.  **[1660334_28190089a25f4c579e6f35c03e011a76_0]** 
- **Katarina Pance, Ph.D.**, an investor at SR One, has joined Veradermics' board of directors.  **[1660334_28190089a25f4c579e6f35c03e011a76_0]**

Verrica Pharmaceuticals (VRCA)